| 前收盘价格 | 312.12 |
| 收盘价格 | 317.20 |
| 成交量 | 189,286 |
| 平均成交量 (3个月) | 236,033 |
| 市值 | 32,309,166,080 |
| 市盈率 (P/E TTM) | 70.30 |
| 预期市盈率 (P/E Forward) | 50.76 |
| 价格/销量 (P/S) | 6.23 |
| 股市价格/股市净资产 (P/B) | 6.80 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2026 |
| 营业毛利率 | -9.40% |
| 营业利益率 (TTM) | 0.99% |
| 稀释每股收益 (EPS TTM) | -3.69 |
| 季度收入增长率 (YOY) | 48.60% |
| 总债务/股东权益 (D/E MRQ) | 28.49% |
| 流动比率 (MRQ) | 1.96 |
| 营业现金流 (OCF TTM) | 212.02 M |
| 杠杆自由现金流 (LFCF TTM) | -120.68 M |
| 资产报酬率 (ROA TTM) | -3.22% |
| 股东权益报酬率 (ROE TTM) | -11.44% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | BeOne Medicines Ltd. | 看涨 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.25 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 17.31% |
| 机构持股比例 | 43.94% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Capital International, Inc./Ca/ | 31 Dec 2025 | 307,660 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 425.00 (RBC Capital, 36.48%) | 购买 |
| 中 | 411.00 (31.98%) | |
| 低 | 405.00 (Barclays, 30.05%) | 购买 |
| 平均值 | 413.00 (32.62%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 316.99 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 27 Feb 2026 | 405.00 (30.05%) | 购买 | 316.99 |
| Guggenheim | 27 Feb 2026 | 410.00 (31.66%) | 购买 | 316.99 |
| RBC Capital | 27 Feb 2026 | 425.00 (36.48%) | 购买 | 316.99 |
| Truist Securities | 27 Feb 2026 | 412.00 (32.30%) | 购买 | 316.99 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合